Lambert-Eaton Myasthenic Syndrome

Firdapse NDA Submitted for Lambert-Eaton Myasthenic Syndrome

By April 02, 2018

Results from the Phase 3 trial showed that the Quantitative Myasthenia Gravis (QMG) score at baseline to day 14 changed from 6.4 to 6.7 in the amifampridine group vs. 5.6 to 7.9 for the placebo group.